Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | KRAS | P01116 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1489210 | 0.80 | CA12 (0.52) | CES2CES1RAB9AALDH1A1CFTR | |
| SCHEMBL6989232 | 0.76 | CES2 (0.40) | CES2CES1RAB9AALDH1A1CFTR | |
| SCHEMBL13527491 | 0.75 | RAB9A (0.53) | CES2CES1RAB9APOLBKMT2A | |
| SCHEMBL6989492 | 0.75 | CES2 (0.37) | CES2CES1RAB9AALDH1A1POLB | |
| SCHEMBL28015207 | 0.74 | POLB (0.44) | CES2CES1RAB9AALDH1A1CFTR | |
| SCHEMBL14454258 | 0.73 | CES2 (0.52) | CES2CES1CRBNPOLBHDAC1 | |
| SCHEMBL1202579 | 0.73 | GAA (0.52) | CES2CES1RAB9AALDH1A1CRBN | |
| SCHEMBL1203645 | 0.72 | ITGB2 (0.47) | CES2CES1CRBNHDAC1PREP | |
| SCHEMBL6989227 | 0.72 | RAB9A (0.43) | CES2CES1RAB9ACRBNPOLB | |
| SCHEMBL283962 | 0.71 | CES2 (0.54) | CES2CES1RAB9ACRBNPREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1359147-A1 | 4,4-disubstituted-1,4-dihydro-2H-3,1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and processes for making the same | Bristol-Myers Squibb Pharma Company (US) | 2003-11-05 | — | — | EP | disclosed |
| EP-0929533-B1 | 4,4-DISUBSTITUTED-1,4-DIHYDRO-2H-3,1-BENZOXAZIN-2-ONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS AND INTERMEDIATES AND PROCESSES FOR MAKING THE SAME | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-09-03 | — | — | EP | disclosed |
| US-6492515-B2 | FOR THERAPY OF HIV INFECTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-10 | — | — | US | disclosed |
| US-20020040138-A1 | 4,4-disubstituted-1, 4-dihydro-2H-3, 1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and intermediates and processes for making the same | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-04-04 | — | — | US | disclosed |
| US-6303780-B1 | 4,4-disubstituted-1,4-dihydro-2h-3,1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and intermediates and processes for making the same | DUPONT PHARMACEUTICALS COMPANY | 2001-10-16 | — | — | US | disclosed |
| US-6140499-A | 4,4-disubstituted-1,4-dihydro-2H-3,1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and intermediates and processes for making the same | DUPONT PHARMACEUTICAL COMPANY (US) | 2000-10-31 | — | — | US | disclosed |
| EP-0929533-A1 | 4,4-DISUBSTITUTED-1,4-DIHYDRO-2H-3,1-BENZOXAZIN-2-ONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS AND INTERMEDIATES AND PROCESSES FOR MAKING THE SAME | Du Pont Pharmaceuticals Company (US) | 1999-07-21 | — | — | EP | disclosed |
| US-5874430-A | COMPOUNDS AS PROTEASE, REVERSE TRANSCRIPTASE INHIBITORS FOR DIAGNOSIS | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-02-23 | — | — | US | disclosed |
| WO-1998014436-A1 | 4,4-DISUBSTITUTED-1,4-DIHYDRO-2H-3,1-BENZOXAZIN-2-ONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS AND INTERMEDIATES AND PROCESSES FOR MAKING THE SAME | DUPONT PHARMACEUTICALS COMPANY (US) | 1998-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040138-A1 | 4,4-disubstituted-1, 4-dihydro-2H-3, 1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and intermediates and processes for making the same | DHX15, CYP4X1, DPYD | CES2 732/4885CES1 249/4885RAB9A 4185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.